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The use of CRISPR-Cas9 as a therapeutic reagent is hampered by its off-target 
effects. The determination of the Cas9 crystal structure (Nishimasu, H., et al., 2014) 
enabled scientists to rationally design mutant Cas9 proteins (enhanced Specificity 
Cas9 (eSpCas9) and Cas9-High Fidelity (Cas9-HF)) with higher specificities than 
wild-type Cas9 (WT-Cas9). Their design was based on the hypothesis that 
weakening non-specific interactions between a Cas9-RNA complex and its substrate 
DNA would reduce both on-target and off-target activities alike. Since on-target 
activity is generally much higher than off-target activity, these mutant Cas9 variants 
would show higher specificities than WT while retaining on-target activities. 
However, it has been reported that both eSpCas9 and Cas9-HF were poorly active at 
some target sites (Kim, S. et al., 2017 ; Kulcsar, P.I., et al., 2017; Zhang, D., et al., 
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2017) calling for alternative approaches to improve Cas9 specificity. More recently, 
three additional Cas9 variants, termed evoCas9, HypaCas9 and xCas9-3.7 with 
improved specificity and activity were developed, reflecting unmet needs in this field. 
Although rationally designed S. pyogenes Cas9 (SpCas9) variants that display 
higher specificities than the wild-type SpCas9 protein are available, these attenuated 
Cas9 variants are often poorly efficient in human cells. Here, we develop a directed 
evolution approach in E. coli to obtain Sniper-Cas9, which shows high specificities 
without sacrificing on-target activities in human cells. Unlike other engineered Cas9 
variants, Sniper-Cas9 shows WT-level on-target activities with extended or truncated 
sgRNAs with further reduced off-target activities and works well in a preassembled 
ribonucleoprotein (RNP) format to allow DNA-free genome editing. 
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RNA-guided endonucleases are currently used powerful tool for genome 
editing and are widely used in research. Streptococcus pyogenes Cas9 (SpCas9), 
which is one of the type II clustered regularly interspaced short palindromic repeat 
(CRISPR) - associated protein 9 (CRISPR-Cas9) systems, is a most validated Cas9 
enzyme for genome editing. Cas9 system has advantage of being a user-friendly tool 
for targeting and modifying a specific DNA sequences. Other DNA-binding 
endonuclease proteins such as zinc finger nucleases (ZFNs) and transcription 
activator-like effector (TALE) (Kim Y, et al., 2013) nucleases need reengineered 
each time in order to bind different target DNA sequences. In CRISPR-Cas9, DNA 
targeting element is not protein itself, but a single-guide RNA (sgRNA). So, Cas9 
system is easier to handle because it requires modification at RNA level, not at 
protein level. 
However, the clinical application of Cas9 is potentially limited by off-target 
effect, which is unwanted nucleases activities in unwanted target site. Several groups 
have researched various method to overcome this issue. First, control of activity of 
Cas9 via direct delivery ribonucleoprotein (RNP) (Kim, S et al., 2014) complex. 
Second, engineering of the sgRNAs, truncation of length or additional guanine 
(ggX20) (Kim, S et al., 2014) to restrict targetable sites and increase complexity. 
Third, engineering the Cas9 protein itself: The determination of the Cas9 crystal 
structure enabled scientists to rationally design mutant Cas9 proteins (enhanced 
specificity Cas9 (eSpCas9) and Cas9-high fidelity (Cas9-HF)) with higher 
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specificities than wild-type Cas9 (WT-Cas9) (Kleinstiver, B.P., et al., 2016; 
Slaymaker, I.M., et al., 2016). Their design was based on the hypothesis that 
weakening non-specific interactions between a Cas9-RNA complex and its substrate 
DNA would reduce off-target activity (Kleinstiver, B.P., et al., 2016; Slaymaker, I.M., 
et al., 2016). In the case of espCas9 (1.1), they hypothesized that Cas9 cutting 
efficiency increases when target DNA strand separation is stabilized. Off-target 
sequences have less complementarity to sgRNA than on-target sequences, they have 
a higher propensity to reform double helices and decrease Cas9 efficiency. In view 
of this, they changed the positive charge residues in HNH/RuvC domain to 
destabilize the basal strand separation by reducing the interaction between the 
domain and negatively charged DNA (Slaymaker, I.M., et al., 2016). In another Cas9, 
Cas9-HF1 was designed to reduce the interaction between Cas9 and phosphate 
backbone of the target DNA strand, instead of weakening the interaction between 
Cas9 and non-target DNA strand based on the Cas9-RNA-DNA structures 
(Kleinstiver, B.P., et al., 2016; Nishimasu, H., et al., 2014). In the other Cas9, 
HypaCas9 was designed by researching the specificities of espCas9 and Cas9-HF1 
through single molecule FRET. This study revealed espCas9 (1.1) and Cas9-HF1 
each stall in and inactive form after binding to a target site and proposed that this 
stalling leads to their enhanced specificity. Additionally, mutations in the REC3 
domain facilitate this stall. Based on this new structural study, HypaCas9 with 
mutations in the REC3 domain was designed (Chen J.S., et al., 2017). Since on-target 
activity is generally much higher than off-target activity, these mutant Cas9 variants 
would show higher specificities than WT-Cas9 while retaining on-target activity.  
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As opposed to rational approaches, a randomized screening allows the 
exploration of a wide mutational library and the isolation of suitable residues directly 
in vivo, potentially enabling the identification of SpCas9 variants with higher fidelity. 
Recently, two groups reported engineered Cas9 variants using directed evolution 
termed evoCas9 (Casini, A., et al., 2018) and xCas9 (Chen, J.S., et al., 2017). 
evoCas9 was engineered through a single round of directed evolution screening 
performed in Saccharomyces cerevisiae. xCas9 was optimized through phage-
assisted continuous evolution to evolve an expanded PAM and improved specificity. 
In this study, we reasoned that directed evolution of Cas9 in E. coli could 
lead to Cas9 variants with high specificity without sacrificing on-target activities. 
The system my colleagues used consists of E. coli strain BW25141 and a plasmid 
containing the lethal ccdB (Chen, Z et al., 2017 ; Kleinstiver, B.P., et al., 2015) gene 
and the Cas9 target sequence : The disruption of the ccdB gene by Cas9-mediated 
plasmid DNA cleavage is essential for cell survival, creating a positive selection 
pressure. In addition, a Cas9 off-target sequence that differs from the on-target 
sequence by a few mismatches is introduced in the E. coli genomic DNA: Double 
strand breaks (DSBs) in E. coli genomic DNA lead to cell death. We combined such 
negative selection pressure with ccdB plasmid-based positive selection pressure to 
develop ‘Sniper-screen’, which selects for Cas9 variants with increased specificities. 
Note that Cas9 variants with poor on-target activities or poor specificities cannot 
survive in this selection system.  
 We using Sniper-screen, SpCas9 mutant libraries with random errors in 
the whole Cas9 sequence were constructed using three different kits, resulting in 
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library complexities of up to 107 overall. The set started with more lenient screening 
conditions and progressed toward more stringent conditions: DNA shuffling was 
performed in the middle of the process to enrich the diversity. After the final selection 
steps for screening, the pooled libraries showed higher specificities than WT-Cas9. 





Materials and Methods 
1. Plasmid construction.  
Each type of plasmid used in the Sniper-screen contains replication origins 
and resistance markers that are compatible with each other. The ccdB plasmid (p11-
lacY-wtx1) was a kind gift from the Zhao lab. It was double-digested with SphI and 
XhoI enzymes, which was ligated to oligos containing target sequences with T4 
DNA ligase. The sgRNA vector was constructed with a temperature-sensitive Psc101 
replication origin12 (from pgrg36, a kind gift from Nancy Craig), tetR (from the tn10 
locus of ElectroTen-Blue Electroporation Competent Cells, Agilent), a Kanamycin 
resistance marker, the pltetO1 promoter and the sgRNA sequence containing two 
BsaI sites (synthesized at Bioneer). The components were PCR-amplified and 
Gibson assembled (NEBuilder HiFi DNA Assembly kit, NEB). The guide RNA 
sequences to EMX1 with various mismatches were cloned into the vector after BsaI 
digestion. The Cas9 library plasmid was derived from human codon-optimized WT-
Cas9 (p3s-Cas9HC; Addgeneplasmid#43945)37, dual CMV-pltetO1 (synthesized at 
Bioneer) and the p15a replication origin and chloramphenicol resistance marker 
(from the PBLC backbone, Bioneer). The components were Gibson assembled.  
 
2. EMX1 genome insertion.  
Human EMX1 containing various sgRNA target sequences (~500bp) was 
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PCR-amplified and integrated into the pgrg3612 vector between the NotI and XhoI 
sites. The cloned pgrg36-EMX1 vector was then transformed into the BW25141 
strain to integrate the EMX1 sequence into the tn7 site in the genomic DNA. EMX1-
BW25141 was selected using the standard pgrg36 protocol. 
 
3. Library construction.  
SpCas9 mutant libraries were constructed using three independent 
protocols. For the first library, the Cas9 library plasmid was transformed into XL1-
red competent cells (Agilent), which were grown according to instructions in the 
vendor's manual. For the second and third libraries, error-prone PCR was performed 
on whole WT-SpCas9 from Cas9 library plasmid sequences using Genemorph II 
(Agilent) and Diversify PCR random mutagenesis (Clontech) kits under low error 
rate (0–5 mutations per kb) conditions with primers designed for Gibson Assembly; 
PCR products were subsequently gel purified (4.3kb). The purified randomly 
mutagenized library and the backbone of the Cas9 library plasmid (double-digested 
with BamHI and XbaI, followed by gel purification of the 3kb fragment) were 
Gibson assembled. The assembled libraries were transformed into Endura™ 
electrocompetent cells (Lucigen) and incubated on chloramphenicol LB plates 
(12.5μg/mL) at 37°C overnight. A total of 3×106 colonies were obtained for each 
library, resulting in a library complexity of 107 overall. Pooled library plasmids were 




4. Positive and negative screening for evolving SpCas9. 
BW25141-EMX1 was co-transformed with the ccdB and sgRNA plasmids. 
The transformed BW25141-EMX1 cells were plated on ampicillin 
(50μg/mL)/kanamycin (25μg/mL) LB plates, which were then incubated overnight 
at 32°C. Transformants were cultured in liquid S.O.B. medium containing 0.1% 
glucose, ampicillin, and kanamycin until the OD 600 reached 0.4 for 
electrocompetent cell production (Sniper-Screen). Hundred nano grams of SpCas9 
from each library was transformed into 50μL of electrocompetent Sniper-Screen 
cells using a Gene Pulser (Gene Pulser II, Bio-Rad) following the manufacturer’s 
instructions. Transformed Sniper-screen cells were mixed with 250μL of S.O.C. 
medium. Twenty-five microliters of transformed cells was incubated without ATC 
(Sigma-Aldrich) and 250μL of cells was incubated with 10ng/mL ATC for 1h at 37°C. 
The Sniper-screen cells recovered in the absence of ATC were plated on 
chloramphenicol/kanamycin LB plates (nonselective conditions) and cells recovered 
in the presence of ATC were plated on chloramphenicol/kanamycin/arabinose 
(1.5mg/mL, Sigma-Aldrich) LB plates (selective conditions) containing 100ng/mL 
ATC followed by overnight culture at 32°C. Viable colonies were counted using 
OpenCFU software and the survival frequency was calculated (survival 
frequency=the number of colonies on a selective plate/the number of colonies on a 
non-selective plate×10). Colonies on the selective plates from three libraries were 
pooled and incubated in chloramphenicol-containing LB medium overnight at 42°C 
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to clear ccdB and sgRNA plasmids. Screened SpCas9 variant plasmids were purified 
using a midi prep kit (Macherey-Nagel) and 10ng of pooled library was continuously 
transformed into the Sniper-screen until the survival frequency reached a plateau.  
The ATC concentration in the selective conditions was maintained as 100ng/mL for 
the two-mismatch conditions and as 10ng/mL for the one-mismatch condition. 
Selected SpCas9 gene variants obtained from the two-mismatch conditions were 
shuffled to increase library diversity (DNA-Shuffling Kit, Jena Bioscience) 
following the manufacturer’s instructions. Screening of the shuffled SpCas9 library 
was performed again under the one-mismatch condition, and 100 colonies on a 
selective plate after six rounds of screening were individually cultured in 
chloramphenicol-containing LB medium at 42°C to obtain evolved SpCas9 mutant 
plasmids. Each plasmid was Sanger sequenced and the top three most frequent 
variants were chosen to be tested in a human cell line. 
 
5. Plasmids encoding Cas9 variants and sgRNA. 
The WT-Cas9-encoding plasmid (p3s-Cas9HC; Addgene plasmid #43945) and the 
sgRNA plasmid (pRG2; Addgene plasmid #104174)4 have been described 
previously. Plasmids encoding human codon-optimized eSpCas9 (1.1) and Cas9-
HF1 (p3s-eCas9 (1.1), Addgene plasmid #104172; p3s-Cas9-HF1, Addgene plasmid 
#104173) were Gibson assembled into the p3s-Cas9HC plasmid backbone to change 
the location of the nuclear localization signal (NLS) from the N-terminus to the C-
terminus. Human codon-optimized evoCas9, HypaCas9, and xCas9–3.7 (evoCas9, 
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Addgene plasmid #107550, HypaCas9, Addgene plasmid #101178 and xCas9–3.7, 
Addgene plasmid #108379) constructs were created by Gibson assembly of 
sequences containing the necessary site mutations into the p3s-Cas9HC plasmid 
backbone. All constructs were confirmed by Sanger sequencing. Human codon 
optimized WT-BE3 and Sniper-BE3 were made by exchanging WT-SpCas9 from 
CMV-BE3 (a kind gift from David Liu; Addgene plasmid # 73021) with WTCas9 
and Sniper-Cas9 derived from p3s-Cas9HC.  
 
6. Cell culture and transfection conditions.  
HEK293T cells (ATCC, CRL-11268) were maintained in DMEM medium 
supplemented with 10% FBS and 1% antibiotics. For WT Cas9, eSpCas9 (1.1), 
Cas9-HF1, and Sniper Cas9-mediated genome editing, HEK293T cells were seeded 
into 48-well plates at 70–80% confluency before transfection and transfected with 
Cas9 variants expression plasmids (250ng) and crRNA plasmids (250ng) using 
lipofectamine 2000 (Invitrogen). For base editing, HEK293T cells (1.5×105) were 
seeded on 24-well plates and transfected at ~80% confluency with BE plasmid 
(Addgene plasmid #73021) (1.5µg) or the Sniper-Cas9 expression plasmid and 
sgRNA plasmid (500ng) using Lipofectamine 2000 (Invitrogen). Genomic DNA was 
isolated with the DNeasy Blood & Tissue Kit (Qiagen) 72h post transfection. 
 
7. Recombinant Cas9 protein production.  
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Recombinant WT-Cas9 and Sniper-Cas9 proteins were purified from E. coli. 
The Cas9 DNA sequence was sub-cloned into pET28-b(+). Recombinant Cas9 
protein containing a NLS, the HA epitope, and a His-tag at the N-terminus was 
expressed in strain BL21(DE3), purified using Ni-NTA agarose beads (Qiagen), and 
dialyzed against 20mM HEPES pH 7.5, 150mM KCl, 1mM DTT, and 10% glycerol. 
The purified Cas9 protein was concentrated using an Ultracel 100K cellulose column 
(Millipore). The purity and concentration of the Cas9 protein were analyzed by SDS-
PAGE.  
 
8. Preparation of guide RNAs for RNP production.  
RNA was in vitro-transcribed through run-off reactions with T7 RNA 
polymerase using a MEGA shortscript T7 kit (Ambion) according to the instructions 
in the manufacturer’s manual. Templates for sgRNA or crRNA were generated by 
annealing and extension of two complementary oligonucleotides as described 
previously. Briefly, sgRNA templates were generated by annealing two 
complementary oligonucleotides purchased from Macrogen. These oligonucleotides 
were reverse-phase-purified using the vendor’s MOPC purification method and 
quality-checked using MALDI-TOF. sgRNA templates were incubated with T7 RNA 
polymerase in reaction buffer (40 mM Tris-HCl, 6 mM MgCl2, 10 mM DTT, 10 mM 
NaCl, 2 mM spermidine, NTP, RNase inhibitor, at pH 7.9) for 8 h at 37 °C. 
Transcribed sgRNAs were pre-incubated with DNase I to remove template DNA, 
and purified using PCR purification kits (Macrogen). For 5′OH sgRNA generation 
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only, the 5′-triphosphate was removed from guide RNAs with CIP (New England 
BioLabs) as follows: 10µg of in vitro-transcribed RNA was treated with 250 units of 
CIP for 3 h at 37°C in the presence of 100 units of RNase inhibitor (New England 
BioLabs). Following CIP treatment (or following in vitro transcription in the case of 
5′PPP sgRNA), the RNA was cleaned up using a miRNeasy Mini kit (Qiagen). 
 
9. RNP delivery.  
To introduce DSBs in HEK293T cells using an RNP complex, 2× 104 cells 
were transfected with WT-Cas9 protein or Sniper-Cas9 (4μg) pre-mixed with in 
vitro-transcribed sgRNA (4μg). To make RNP complexes, Cas9 protein in storage 
buffer (20mM HEPES pH 7.5, 150mM KCl, 1mM DTT, and 10% glycerol) was 
mixed with sgRNA dissolved in nuclease-free water and incubated for 10min at room 
temperature. RNP complexes were electroporated into HEK293T cells with a Neon 
transfection system (ThermoFisher) using the following settings: 1300V, 30ms, and 
1 pulse. Genomic DNA was isolated with a DNeasy Blood & Tissue kit (Qiagen) 
48h post transfection. 
 
10. Whole-genome and Digenome sequencing. 
Genomic DNA (1µg) was fragmented to the 400- to 500-bp range using the 
Covaris system (Life Technologies) and blunt-ended using End Repair Mix (Thermo 
Fischer). Fragmented DNA was ligated with adapters to produce libraries, which 
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were then subjected to whole genome sequencing (WGS) using a HiSeq X Ten 
Sequencer (Illumina) at Macrogen. WGS was performed at a sequencing depth of 
30–40×. DNA cleavage sites were identified using Digenome 1.0 programs. 
 
11. Targeted deep sequencing. 
Target sites and potential off-target sites were analyzed by targeted deep-
sequencing appropriate primers. Deep-sequencing libraries were generated by PCR. 
TruSeq HT Dual Index primers were used to label each sample. Pooled libraries were 
subjected to paired-end sequencing using MiniSeq (Illumina). 
 
12. iPS cell genome editing. 
 iPSC generation has been described previously. Briefly, BJ cells were 
cultured in DMEM supplemented with 10% FBS. A total of 1 × 106 BJ cells were 
resuspended in a single-cell suspension using trypsin and were electroporated with 
three reprogramming plasmids (pCXLE-hOCT4-shp53 (Addgene plasmid #27077), 
pCXLE-hSK (Addgene plasmid #27078), and pCXLE-hUL (Addgene plasmid 
#27080)) using the Neon Transfection System (Invitrogen). Neon transfection 
conditions used were 1400 V, 20 ms, 2 time pulses for BJ cells. The transfected cells 
were seeded on a 6-cm dish and were cultured in BJ cell culture media for five days. 
The cells were then replated at a density of 1−3 × 104 cells per well in a 6-well plate 
pre-coated with vitronectin (STEMCELL Technologies) and cultured in BJ cell 
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culture media for two more days; finally, the medium was changed to iPS cell 
induction medium until all the iPSC colonies were harvested. CRISPR/ Cas9-
mediated genome editing of iPS cells (ATCC CRL-2522) was carried out as follows. 
iPSCs maintained on vitronectin-coated dishes (STEMCELL Technologies) in 
TeSR-E8 medium (STEMCELL Technologies) were detached using Gentle Cell 
Dissociation Reagent (STEMCELL Technologies). We used a four-dimensional 
nucleofector from Amaxa in combination with a P3 Primary Cell Kit for transfection. 
Four micrograms of recombinant Streptococcus pyogenes Cas9 (Toolgen) and 1 μg 
of 5 ′-OH sgRNA were incubated for 20min prior to electroporation to generate 
Cas9-gRNA RNP complexes. A total of 2×105 iPSCs re-suspended in P3 buffer were 
added to the pre-incubated Cas9-gRNA RNP complexes. Cells were nucleofected 
using program CA-137. Electroporation-only controls were nucleofected without 
RNP complexes using the same conditions. One microgram of enhanced green 
fluorescent protein (EGFP) messenger RNA (TriLink) was nucleofected into cells 
for the green fluorescent protein control under the same conditions. Cells were 
counted using Countess II Fl (Life technologies). Images of the cells were taken 
using an EVOS Fl Cell Imaging System (Thermo Fisher Scientific). 
 
13. T-cell genome editing. 
 CRISPR/Cas9-mediated genome editing of T cells was carried out as 
follows. Human peripheral blood pan-T cells were purchased from STEMCELL 
Technologies. Upon thawing, the T cells were allowed to rest overnight in RPMI 
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supplemented with FBS, hrIL-2 (Peprotech, 50U/mL), and hrIL-7 (Peprotech, 
5ng/mL) prior to activation. Activation was induced by the addition of Dynabeads 
Human T Activator anti-CD3/28 (ThermoFisher SCIENTIFIC) at a bead-to-cell ratio 
of 3:1 in RPMI supplemented with 10% FBS. 3 days later, the activating beads were 
removed and electroporation was carried out using an Amaxa P3 Primary Cell kit 
and 4D-Nucleofecter (Lonza). Eight micrograms of recombinant S. pyogenes Cas9 
(Toolgen) and 2μg of 5 ′-OH sgRNA were incubated for 20min prior to 
electroporation to generate Cas9-gRNA RNP complexes. A total of 5×105 stimulated 
T cells re-suspended in P3 buffer were added to the pre-incubated Cas9-gRNA RNP 
complexes. Cells were nucleofected using program EO-115. Following 
electroporation, cells were seeded at 5×105 cells per mL in RPMI supplemented with 
10% FBS, hIL-2 (Peprotech, 50U/mL), and hIL-7 (Peprotech, 5ng/mL). 
Electroporation-only controls were nucleofected without RNP complexes using the 
same conditions. Cells were counted using Countess II Fl (Life technologies). 







1. Simultaneous positive and negative selection using E. coli 
 
My colleagues first inserted a 500-bp PCR product containing an EMX1 
fragment into the genomic DNA of the BW25141 strain using a protocol involving 
transposase (McKenzie, G.J. et al,. 2006). (Fig. 1a and Fig. 2) The resulting 
BW25141-EMX1 strain was transformed with two plasmids (Fig. 1b): a plasmid 
expressing ccdB under the control of the pBAD promoter, which is induced by 
arabinose, and a plasmid expressing an sgRNA under the control of the pltetO1 
promoter, which is induced by anhydrotetracycline (ATC). A target sequence with 
mismatches relative to the EMX1 site was inserted into the ccdB plasmid and the 
matching guide sequence was inserted into the sgRNA plasmid. These EMX1 on-
target and off-target sequences were chosen because off-target activities had been 
carefully tested at the EMX1 site previously using a series of mismatched sgRNAs 
(Hsu, P.D., et al., 2013). To screen for Cas9 variants without attenuated on-target 
activity, a 21-mer EMX1 sgRNA with the 5’ guanine mismatched to the target 
sequence (gX20), which showed diminished on-target activities with engineered 
Cas9s (Fig. 1b), was used. In a Sniper screen, the resulting E. coli strain is 
electroporated with a pooled library expressing mutant Cas9 variants under the 
control of a CMV-pltetO1 dual promoter induced by ATC. There are four possible 
outcomes with respect to DNA cleavage in the ccdB plasmid and the genomic DNA 
(Fig. 1a): Only a mutant variant of Cas9 that discriminates the on-target sequence 
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present in the ccdB plasmid from the off-target sequence present in the E. coli 
genomic DNA can survive. This system uses separate Cas9 and sgRNA plasmids, 
making it easy to change sgRNA-encoding and target sequence-containing plasmids 
in subsequent rounds of selection. Because Cas9 can also be expressed in 
mammalian cells via the CMV promoter, it is possible to check the on-target and off-
target activity of the pool obtained in each round. In addition, Cas9 and sgRNA 
expression are controlled by the pltetO1 promoter, allowing regulation of gene 
expression by up to 5000-fold (Lutz, R. et al., 1997). By increasing the concentration 
of ATC, the screening conditions become more lenient for ccdB cleaving positive 
selection and harsher for genomic DNA cleaving negative selection. Such 
adjustments were necessary to find the optimum conditions at which control 
experiments using WT-Cas9 and a null vector showed a large window for cleavage 




Figure 1. Gene knockout screens using pooled sgRNA libraries (a) Schematic of 
the Sniper-screen. DSB, double strand break; NC, no cleavage. Cell death is 
indicated by red type. (b) Plasmid design with sample sgRNA and target sequences 








Figure 2. Integration of EMX1 into genomic DNA of BW25141 strain. The 
successful integration of EMX1 into the genomic DNA of the BW25141 strain was 
confirmed by colony PCR amplification of the Tn7 attachment site in the glmS gene. 
A 678 bp product was observed in the absence of an EMX1 insertion whereas a 1404 
bp product was observed in the presence of an EMX1 insertion. Eight different 
colonies were picked; amplification of DNA from #1 and #6 resulted in single bands 







Figure 3. Control reactions for four different Sniper-screens. Control reactions 
for four different Sniper-screens were performed with plasmids containing WT-Cas9 
or no insert (null). E. coli death was measured by comparing colony forming units 
(CFU) on plates with inducers (chloramphenicol + kanamycin + arabinose + ATC; 
CKA + ATC) and without inducers (chloramphenicol + kanamycin; CK). In both 
cases, under inducing conditions 100~10,000-fold more E. coli death was observed, 
caused by the formation of DSBs in genomic DNA (WT-Cas9) or expression of the 




2. Construction of the Cas9 library and Sniper screen.  
 
SpCas9 mutant libraries with random errors in the whole Cas9 sequence 
were constructed using three different kits, resulting in library complexities of up to 
107 overall. Two independent sets of screenings were performed using the libraries 
(Fig. 4). The first set started with more lenient screening conditions and progressed 
toward more stringent conditions: DNA shuffling was performed in the middle of 
the process to enrich the diversity. The second set employed harsh conditions without 
DNA shuffling. After the final selection steps for both screening sets, the pooled 
libraries were tested in mammalian cells to measure the specificities of the Cas9 
variants compared to WT-Cas9 (Fig. 5). The pooled libraries showed higher 
specificities than WT-Cas9; the first set was more specific than the other set. One 
hundred colonies were picked from both sets and the Cas9-encoding DNA sequences 
were fully sequenced. Three Cas9 variants were identified from the first set, which 
were designated Clone-1, Clone-2 and Clone-3 (Fig. 6). The mutations were 
dispersed throughout domains revealed in the crystal structure (Nishimasu, H., et al., 
2014); none of them overlapped with those in rationally-designed Cas9 variants (Fig. 
7). Site-directed mutagenesis analyses revealed that no single point mutation 
drastically improved the specificity of WT-Cas9 (Fig. 8). Since my co-workers 
performed the DNA shuffling reaction in the middle of our screening, we assumed 






Figure 4. Gene knockout screens using pooled sgRNA libraries. EMX1 sgRNAs 
mismatched relative to the WT EMX1 sequence (top row). 20mer EMX1 target 
sequence 56: 5th and 6th positions were substituted as designated in upper case 
characters; 1718: 17th and 18th positions were substituted as designated in upper 
case characters; 7: 7th position was substituted as designated in upper case characters; 
17: 17th position was substituted as designated in upper case characters. The 








Screening A: Three types of libraries (XL-1 Red, derived from XL-1 Red competent 
cells from Agilent; Aligent, derived using the Genemorph II error prone PCR kit 
from Agilent; Clontech, derived using the Diversify PCR random mutagenesis kit 
from Clontech) were subjected to the Sniper-screen in BW251414-EMX1(56) cells 
with sgRNA (2 mismatches, at positions 5 and 6) and ccdB plasmids. 1G1S (1718): 
Screening of the results of the library screen in BW25141-EMX1 (1718). 
1G2S(1718): Screening of the results from the 1G1S(1718) screen in BW25141-
EMX1 (1718). 1G3S(1718): Screening of the results from the 1G2S(1718) screen in 
BW25141-EMX1 (1718). 2G1S(7): Screening of the shuffled library generated from 
the results of the 1G3S(17) screen in BW25141-EMX1 (7). 2G2S(7): Screening of 
the results from the 2G1S(7) screen in BW25141-EMX1 (7). 2G3S(17): Screening 
of the results from the 2G2S(7) screen in BW25141-EMX1 (17). 2G4S(7): Screening 
of the results from the 2G3S(7) screen in BW25141-EMX1 (7). 2G5S(17): Screening 
of the results from the 2G4S(7) screen in BW25141-EMX1 (17). DNA shuffling 




Screening B: Three types of libraries (XL-1 Red, derived from XL-1 Red competent 
cells from Agilent; Aligent, derived using the Genemorph II error prone PCR kit 
from Agilent; Clontech, derived using the Diversify PCR random mutagenesis kit 
from Clontech) were subjected to the Sniper-screen with sgRNA (1 mismatch at 
position 7) and ccdB plasmids. 1G1S(7) (1Generation1Series): Screening of the 
results from the first library screen in BW25141-EMX1 (7). 1G2S(7): Screening of 
the results from the 1G1S screen in BW25141-EMX1 (7). 1G3S(7): Screening of the 
results from the 1G2S(7) screen in BW25141-EMX1 (7). 1G4S(17): Screening of the 
results from the 1G3S(7) screen in BW25141-EMX1 (17). 1G5S(17): Screening of 



























































Figure 5. On/Off target activities of Cas9 variants from screenings. (A) On-target 
and off-target activities of WT-Cas9 and the pooled library from two different 
screenings at a target in the human DMD gene in HEK293T cells. (B) On-target and 
off-target activities of three different Cas9 variants (Clone-1, 2 and 3) at a target in 
the human DMD gene in HEK293T cells (C) On-target and off-target activities of 
WT-Cas9 and the pooled library from two different screenings at a target in the 
human EMX1 gene in HEK293T cells. (D) On-target and off-target activities of three 


















Figure 9. On-target and off-target activities of Cas9 variants. On-target and off-
target activities of Cas9 variants compared to WT-Cas9 using sgRNAs variable 
lengths targeting rest of 10 target sites out of 12 targets tested. Specificity ratios were 
determined by dividing indel frequencies at on-target sites by those at respective off-
target sites. sgRNAs with a matched guanine at the 5’ terminus (GX18 or GX19) and 
those with a mismatched guanine (gX17, gX18, gX19 or gX20) are indicated. N/A 
(Not Available): Specificity ratios were not calculated when on-target activities were 








Figure 10. On-target and Off-target sequences. sgRNAs were transcribed by the 
U6 promoter and thus must start with a guanine at the 5’ end, which may (GX19) or 
may not (gX19 or gX20) complement the on-target sequences. I tested six sgRNAs 




4. Comparison of Sniper-Cas9 with other engineered Cas9 
variants.  
 
We next compared the specificities of Sniper-Cas9 with those of other Cas9 
variants by measuring indel frequencies at on-target and off-target sites via targeted 
amplicon sequencing and calculating the ratios of on-target activity to off-target 
activity. In this analysis, we excluded Cas9 variant-sgRNA combinations with less 
than 70% on-target activity relative to WT-Cas9 in complex with 20-mer sgRNAs 
(Fig. 11). Although I tested various combinations of Cas9 variants with truncated 
sgRNAs (Cho, S.W., et al., 2014) or extended sgRNAs (Glenn, T.C, et al., 2011) to 
achieve the highest specificity, only Sniper-Cas9 and WT-Cas9 were compatible with 
these modified sgRNAs. Notably, Sniper-Cas9 achieved the highest specificity ratios 
in 10 out of the 12 on-target/off-target pairs. It should be noted that a specificity ratio 
higher than 1000 is above the detection limit of targeted deep sequencing using 
Illumina MiSeq (0.1%) (Kim, S et al., 2014). In addition, the use of truncated 
sgRNAs is available for only a few targets because such sgRNAs worked at only 9 
out of the 24 targets. To our knowledge, currently it is not possible to predict whether 
a truncated sgRNA will show any on-target activity or a higher specificity ratio prior 
to its design. Western blot analysis showed that expression levels of WT-Cas9 and 
Cas9 variants were comparable in HEK293T cells (Fig. 12). I measured specificity 
ratios of Sniper-Cas9 and other Cas9 variants in Hela cells (Fig. 13). Similar results 










Figure 11. Comparison of Sniper-Cas9 with WT-Cas9 and other engineered 
Cas9s. On-target and off-target activities of Cas9 variant-sgRNA 
combinations with more than 70% on-target activity relative to WT-Cas9. 
Specificity ratios were determined by dividing the on-target activity by the 
off-target activity. For each target, sgRNAs with the highest specificity ratios 






Figure 12. Protein expression test using Western blot. Western blot was 
performed to check the protein expression level of Cas9 variants in HEK293T cells. 











Figure 13. Activity test of Cas9 variants in HeLa cells. On-target and off-target 
activities were measured in HeLa cells using the same sites tested in HEK293T cells. 
Four different targets were tested. Indel frequencies were measured using targeted 




5. On-target and off-target activities of Sniper-Cas9 RNP  
 
To further reduce off-target effects, I delivered Sniper-Cas9 into human 
cells in a preassembled RNP format (Kim, D. et al., 2014). I chose several of the on-
target/off-target pairs with low specificity ratios shown in Figure 11 that used 20-
mer sgRNAs. Sniper-Cas9 RNPs were highly active and more specific than plasmids 
by a factor of 2~16 fold (Fig. 14).  
I also tested a series of guide RNAs containing mismatches relative to the 
on-target sequence to investigate whether Sniper-Cas9 and other Cas9 variants 
tolerate single or double mismatches (Fig. 15). Among three different targets tested, 
direct comparisons between all of the Cas9 variants and WT-Cas9 were possible only 
at the FANCF01 target site owing to the low on-target activities of eSpCas9 (1.1) and 
Cas9-HF1 at other sites. For 13 out of 19 single mismatch positions, Sniper showed 
the highest specificity ratio. Sniper was outperformed by other engineered Cas9s in 
cases with mismatches at the PAM distal end (16th, 18th and 19th). Almost no off-






Figure 14. RNP activity test in HEK 293T cell. On-target and off-target activities 
of WT-Cas9 or Sniper-Cas9 paired with a 20-mer guide sequence delivered via 
plasmid or RNP. Specificity ratios were determined by dividing the on-target activity 













Figure 15. Tolerance of Cas9 variants using serial mutation sgRNA. Tolerance 
of Cas9 variants for sgRNAs containing mismatches relative to HBB02, VEGFA and 
FANCF01 targets. HBB02 was targeted with gX19 sgRNAs and VEGFA was targeted 
with gX20 sgRNAs. FANCF01 was targeted with 1bp or 2bp mismatched GX19 
sgRNAs. Indel frequencies were measured using targeted deep sequencing. Error 




6. Comparison of Sniper-Cas9 with xCas9-3.7.  
 
More recently, Cas9 variants with broad PAM compatibility have been 
reported to show higher specificity (Hu, J.H., et al., 2018). I have tested 20-mer and 
21-mer sgRNAs to characterize on-target and off-target activities of xCas9-3.7 (Fig. 
16). xCas9-3.7 showed specificity ratios that were intermediate between those of 
WT-Cas9 and Sniper-Cas9 at most targets and its on-target activities were attenuated 
significantly at many targets with mismatched 5’ guanines (Fig. 17). It appears that 
although xCas9-3.7 exhibits a broadened PAM compatibility, from NGG to NG, it 
lost compatibility with a 5’guanine. A recent mechanistic study revealed that the 
intrinsic cleavage rates of eSpCas9 (1.1) and Cas9-HF1 are 30 and 39 times slower, 
respectively, than the WT rate, which contributes to the higher specificity ratios of 
the engineered Cas9 variants (Singh, D., et al., 2018). It is speculated that the 
extensive mutagenesis of other engineered Cas9s including xCas9-3.7 lowers the 
intrinsic cleavage rate, resulting in lower on-target activity and a higher specificity 







































Figure 16. Comparison of Sniper-Cas9 with WT-Cas9 and xCas9-3.7. On-target 
and off-target activities of xCas9-3.7 compared to WT-Cas9 and Sniper-Cas9 using 
sgRNAs targeting 10 target sites. Specificity ratios were determined by dividing 
indel frequencies at on-target sites by those at respective off-target sites. sgRNAs 
with a matched guanine at the 5’ terminus (GX19) and those with a mismatched 
guanine (gX19 or gX20) are indicated. N/A (Not Available): Specificity ratios were 
not calculated when on-target activities were less than 70% of the WT plus 20mer 





Figure 17. Comparison of Sniper-Cas9 with xCas9 by dot plot. Dot plots of on-
target indel frequencies normalized to those obtained with WT-Cas9 plus gX20 or 
GX20 sgRNAs. The grey boxed area represents on-target activities higher than 70% 
of the WT-Cas9 activity. The numbers on the x-axis represent the guide sequence 
length including the 5’ guanine; 20: gX19 or GX19, 21: gX20 or GX20. Error bars 




7. Unbiased genome-wide off-target analysis of Sniper-Cas9.  
 
Next, I performed multiplex Digenome-seq using four sgRNAs to test the 
genome-wide specificity of Sniper-Cas9 in the human genome (Kim, D. et al., 2015 ; 
Kim, D. et al., 2016). Sniper-Cas9 cleaved human genomic DNA at far fewer sites 
than did WT-Cas9 (Fig. 18, Fig. 19 and Fig. 20). I analyzed off-target effects at 
candidate off-target sites that were uniquely cleaved by Sniper-Cas9 and that were 
cleaved by both Sniper-Cas9 and WT-Cas9 using targeted amplicon sequencing. No 
off-target mutations were detectably induced by Sniper-Cas9 at sites that were 
cleaved by Sniper-Cas9 alone (Fig. 21). Next, nine candidate sites, commonly 
cleaved by WT-Cas9 and Sniper-Cas9, with the highest DNA cleavage scores were 
selected for each sgRNA and off-target effects were validated at these sites by 
targeted deep sequencing (Fig. 22). Sniper-Cas9 showed lower than WT level off-
target activities at all sites that were analyzed. In conclusion, Sniper-Cas9 did not 
cleave any additional off-target sites in cells, compared to WT-Cas9. 
Having confirmed the high genome-wide specificity of Sniper-Cas9, I 
further compared its specificity to that of other engineered Cas9s at additional GX19 
targets. In this test, I measured off-target activities at validated targets from previous 
GUIDE-seq experiments (Kleinstiver, B.P., et al., 2016 ; Slaymaker, I.M., et al., 
2016 ; Anderson, K. R. et al., 2018 ; Casini, A., et al., 2018) (Fig. 23). Sniper-Cas9 
showed WT-level on-target activities at all additional GX19 targets, whereas Cas9-
HF1, HypaCas9, and evoCas9 showed less than 70% of the WT-level on-target 
activities at some targets. Sniper-Cas9 displayed a specificity comparable to that of 
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other engineered Cas9s at most off-target loci and showed off-target activities that 
were under the detection limit. Sniper-Cas9 showed high off-target activities when 
the sgRNA mismatch was located at the PAM distal end. However, the mismatch 
tolerance at the PAM distal end also enables the use of truncated or extended sgRNAs 
with Sniper-Cas9 to achieve a higher specificity ratio at those sites, as shown 






Figure 18. Circos plot of WT-Cas9 and Sniper-Cas9 from Digenome-seq. 
Genome-wide Circos plots representing DNA cleavage scores for AAVS, DMD, 
FANCF01 and HBB04 obtained with genomic DNA digested with untreated (gray), 





Figure 19. Venn diagrams of WT-Cas9 and Sniper-Cas9 off target candidates 
using Digenome-seq. Venn diagrams showing the number of in vitro cleavage sites 








Figure 21. Validation of off-targets candidate from only Sniper-Cas9 in 
Digenome-seq. Off-target sites for AAVS, DMD and FANC01 validated in HEK293T 
















Figure 22. Validation of off target candidate using Cas9 variants. WT-Cas9, 
eSpCas9 (1.1), Cas9-HF, and Sniper-Cas9 off-target sites for FANCF01 validated in 
HEK293T cells by targeted deep sequencing. Error bars indicate s.e.m. (n = 3) The 












 # targets for specificity 
ratio comparison 
Targets 
Science (eSpCas9) 2 EMX1(1), VEGFA(1) 
Nature (Cas9-HF) 6 
EMX1(1), EMX1(2), FANCF1, 




FANCF2, FANCF6, DNMT1(3), 
DNMT1(4), VEGFA(2), VEGFA(3) 
NBT(evoCas9) 8 
VEGFA2, VEGFA3, EMX1, HEK4, 











Figure 23. Validation of Sniper-Cas9. Validation of off-targets candidate (Yellow 
mark) from Guide-seq from other studies. 70% of WT on-target activity level was 
represented by red line. Off-target sites for EMX1 site 2, FANCF3, RUNX1, ZSCAN2 
and DNMT1 site 4 were validated in HEK293T cells by targeted deep sequencing. 




8. On-target and off-target activities of Sniper-Cas9 BE3. 
 
I also investigated whether the mutations in Sniper-Cas9 can improve the 
specificity of base editors (BEs). To this end, Sniper-Cas9 mutations were introduced 
into base editor 3 (BE3) (Komor, A.C et al., 2016) to create Sniper-Cas9 BE3, which 
was tested in HEK293T cells to determine its base-editing efficiency. Sniper-Cas9 
BE3 was as efficient as WT-BE3 at the EMX1 on-target site. At several pre-validated 
off-target sites that had been identified by Digenome-seq (Kim, D., et al., 2017), 
Sniper-Cas9 BE3 showed much reduced off-target base editing effects (2.4~16.2 fold 
less) compared to WT-BE3 (Fig. 24). In addition, the use of truncated sgRNA further 
eradicated off-target activities to near background level without significant loss of 
on-target activity. This result suggests that the nickase version of Sniper-Cas9 also 
exhibits higher specificity than the WT Cas9 nickase, without sacrificing its on-target 
activity, unlike the nickase form derived from Cas9-HF (HF-BE3), which shows ~70% 
on-target activity compared to WT-BE3 (Rees, H.A., et al, 2017). In addition, Sniper-
BE3 showed WT-level activities with both GX19 and gX19 sgRNAs (Fig. 25), 
unlike base editors derived from Hypa-Cas9 and Cas9-HF1, which were reported to 
show low on-target activities with both forms (Gerhke, J.M et al., 2018). Because 
the number of sgRNAs that could be used to edit specific bases in the target is limited, 
the use of Sniper-Cas9 would increase the number of targetable nucleotides 





Figure 24. Sniper-Base editor activity tests. Base editor (BE3) on-target and off-
target activities measured in HEK293T cells. (−) indicates the absence of sgRNA. 
Substitutions were measured using targeted deep sequencing. Substitution of C5 
(represented by green type) to T was measured. The PAM is shown in blue. Error 






Figure 25. Sniper-Base editor test on multiple targets. Base editor (BE3) on-target 
activities measured in HEK293T cells. Substitutions were measured using targeted 
deep sequencing. Substitution of C (represented by green type) to T was measured. 




9. Sniper-Cas9 RNP as potential therapeutic modality.  
 
Finally, we tested the performance of Sniper-Cas9 RNPs as possible 
therapeutic agents. Primary human T cells and iPS cells were used in this proof-of-
principle study. Although nucleofection of Cas9-encoding plasmid DNA into 
primary cells is possible, the low efficiency and high toxicity of this process 
represent a major hurdle for clinical applications (Mandal, P.K., et al, 2014 ; Shibata, 
M. et al., 2017). The use of RNPs successfully resolved these issues in previous 
therapeutic development studies involving primary cells (Dever, D.P., et al., 2016 ; 
Liang, P., et al., 2015 ; Schumann, K., et al., 2015 ; Ma, H., et al., 2017) with the 
additional advantage of reducient off-target activity compared to plasmid DNA (Kim, 
S et al., 2014).  
The AAVS gene was selected as a hypothetical target because it is 
therapeutically relevant (Lombardo, A., et al., 2011) and its use as safe-harbor site is 
not limited to a particular disease type. In addition, it is the most challenging target 
in terms of the number of candidate genome-wide off-targets identified by 
Digenome-seq (Fig. 18) and the low specificity ratio of a validated off-target site 
containing a single mismatch (Fig. 11). Finally, only Sniper-Cas9 showed WT-level 
on-target activity at this target locus, whereas all of the other engineered Cas9 
variants failed. (Fig. 5) 
We delivered into human T cells and iPS cells the purified Sniper-Cas9 
protein in complex with 5’hydroxyl gX19 sgRNAs to further reduce toxicity caused 
by a triphosphate group present in in vitro-transcribed sgRNAs (Kim, S., et al., 2018). 
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After RNP electroporation, no changes in cell morphology and the number of viable 
cells were observed, indicating that the RNP delivery was not cytotoxic. Importantly, 
Sniper-Cas9 showed WT-level on-target activity with higher specificity ratio, 
compared to WT-Cas9 (1,189 vs. 477), for the off-target site with a single nucleotide 
difference (Fig. 26 and Fig. 27). Both Sniper-Cas9 and WT-Cas9 did not induce off-
target indels at any of the other top nine candidate sites found by Digenome-seq (Fig. 
28), showing that off-target activities were cell-line dependent. Note that gX19 
sgRNAs were not compatible with other engineered Cas9 variants due to their lack 
of on-target activities caused by the mismatched 5’ guanine. In contrast, Sniper-Cas9 
is compatible with 5’ mismatched or truncated or extended sgRNAs and can be 
delivered as purified, preassembled RNPs. 
In summary, we developed Sniper screen in E. coli to create a SpCas9 
variant with increased specificity and full on-target activity. It is anticipated that 
directed evolution of other Cas9 orthologues or Cpf1 by the Sniper screen would 










Figure 27. On-target and off-target activities of WT-Cas9 or Sniper-Cas9 in iPS 
cells and T cells On-target and off-target activities of WT-Cas9 or Sniper-Cas9 
paired with a gX19 guide RNA targeting AAVS and delivered via RNP into iPS cells 
and T cells. Specificity ratios were determined by dividing the on-target activity by 
the off-target activity. (−) indicates the absence of RNP. Error bars indicate s.e.m. (n 







Figure 28. Validation of off-target effect in iPS cells and T cells. WT-Cas9 and 
Sniper-Cas9 off-target sites for AAVS validated in human primary iPS and T cells by 




CMV Promoter PltetO1 promoter WT-Sp-Cas9 BGH polyA signal p15a origin cat 
















































































































PltetO1 promoter gRNA scaffold rrnB T1 terminator pSC101 Ori Rep101(Ts) 


































































 In this study, we reported new Cas9 variant, Sniper-Cas9, with very high 
specificity compared to the wild-type nuclease through Sniper-screen which is 
double selection screening in E.coli.  
We developed Sniper-screening to discovery of Sniper-Cas9, SpCas9 
variant with very high specificity compared to the wild-type nuclease. Because E. 
coli has a faster multiplication time and a higher transformation efficiency than yeast, 
resulting in a larger library scale (~10 fold) and therefore a better screen than the 
yeast-based screening method used by evoCas9 (Casini, A., et al., 2018). 
Furthermore, in sniper-screening, our strategy was performed using sgRNA starting 
with mismatched guanine (gX20 sgRNA), which unlike other Cas9 variants has the 
advantage of having a tolerance in matching the start guanine of the target sequence. 
In addition, evoCas9 is not a pure directed evolution in that it modifies some of the 
mutations from the directed evolution to the rational design method. Additionally, 
Sniper-screen should be more sensitive than other E. coli-based systems in which the 
mismatched site is carried on a plasmid: there is one copy of the genomic DNA and 
thus only one copy of the mismatched site in our system, but a large number of 
plasmids within a single E. coli cell.  
Although rationally designed SpCas9 variants and directed evolution 
variants that display higher specificities than wild-type SpCas9 protein are available 
(Kleinstiver, B.P., et al., 2016 ; Slaymaker, I.M., et al., 2016 ; Casini, A., et al., 2018 ; 
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Chen, J.S., et al., 2017), these attenuated Cas9 variants are often poorly efficient in 
human cells.  
In our knowledge, we found new three mutations combination of advanced 
specificity variants. Of note, the M763I mutation is thought to be a triple complex of 
Cas9, RNA and DNA as a key part of the RuvC II domain (Nishimasu, H., et al., 
2014). The adjacent parts of M763 are involved in binding with Mn2+ ion. These 
core parts bring the REC domain and Nuc lobes of Cas9 protein closer to the DNA 
channel. The mutation of Methionine to isoleucine will affect conformational change 
of Cas9 because it creates a more bulky environment. Therefore, the effect of this 
M763I mutation may help to reduce the non-specific interactions of Cas9-RNA and 
substrate DNA complexes similar to other variants such as eSpCas9 (1.1), Cas9-HF1 
and HypaCas9 because it has decrease off-target Cas9 activity efficiency. 
(Kleinstiver, B.P., et al., 2016; Slaymaker, I.M., et al., 2016; Chen J.S., et al., 2017; 
Jiang, F., et al., 2016) (Fig. 8). In case of F539S of REC domain, the chemical 
properties change from hydrophobic to charge residues, it can bind to DNA more 
strongly than before because distance from the PAM of F539S is close to 11Å. It will 
be effective because the proximal region near the PAM site that plays an important 
role in the target binding. This is consistent with the results of this study with higher 
specificity in the proximal region (Vlandimir, V., et al., 2017). In addition, 
substitution of K890N in the HNN domain may contribute to cleavage of DNA 
efficiently because of better polarity and better accessibility to DNA in terms of 
catalytic activity (Anders, C., et al., 2014). These mutations can’t increase this 
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specificity alone, but these combinations of mutations may affect conformation 
change and on-target activity in a complex way. (Fig. 31) 
Ribonucleoprotein (RNP) delivery is one of the solutions for decrease off 
target effects (Kim, S et al., 2014), but these variants are not suitable for RNP 
because these variants have difficulty in protein purification. In this study, I purified 
Sniper-Cas9 protein and tested on target/off target effect in human cells (HEK293T, 
Hela, iPS and T cells) successfully with higher specificity than WT-Cas9. This can 
be a great advantage when compared to other Cas9 variants. 
In this research, I picked well-defined 12 on target sites which were 
reported in other Cas9 variants study to compare the specificities of Sniper-Cas9 
with those of other Cas9 variants by measuring indel frequencies at on-target and 
off-target sites (Kleinstiver, B.P., et al., 2016; Slaymaker, I.M., et al., 2016). I tested 
various combinations of Cas9 variants with truncated sgRNAs (Cho, S.W., et al., 
2014) or extended sgRNAs (Glenn, T.C, et al., 2011) to achieve the highest 
specificity, only Sniper-Cas9 and WT-Cas9 were compatible with these modified 
sgRNAs (Fig. 11). Sniper-Cas9 achieved the highest specificity ratios in 10 out of 
the 12 on-target/off-target pairs. Unlike Sniper-Cas9, other engineered Cas9 variants 
are not compatible with truncated sgRNAs. Having validated the high genome-wide 
specificity of Sniper-Cas9, I analyzed the off target effect of Sniper-Cas9 and WT-
Cas9 using Digenome-seq (Kim, D. et al., 2015 ; Kim, D. et al., 2016). Sniper-Cas9 
cleaved human genomic DNA at far fewer sites than did WT-Cas9 (Fig. 18, Fig. 19 
and Fig. 20). Accordingly, Sniper-Cas9 has the advantage of making a wider choice 
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when designing sgRNAs than other Cas9 variants and RNP delivery can be used to 
reduce off target effect. 
As part of the application, I also investigated whether the mutations in 
Sniper-Cas9 can improve the specificity of base editor 3 (BE3) (Komor, A.C et al., 
2016). As a result, Sniper-Cas9 BE3 showed much reduced off-target base editing 
effects (2.4~16.2 fold less) compared to WT-BE3 (Fig. 24). In genome-wide analysis 
using Digenome-seq, Sniper-Cas9 BE3 also exhibit higher specificity than WT-Cas9 
BE3. Therefore, Sniper-Cas9 variant is expected to be used in various applications 
with higher specificity. 
Finally, we checked the possibility of the performance of Sniper-Cas9 
RNPs as possible therapeutic agents. Primary human T cells and iPS cells were used 
in this proof-of-principle study. After RNP delivery, any toxicity morphology was 
not observed. Importantly, Sniper-Cas9 showed WT-level on-target activity with 
higher specificity ratio, compared to WT-Cas9 (1,189 vs. 477) (Fig. 27). Also, 
Sniper-Cas9 and WT-Cas9 did not induce off-target indels at any of the other top 
nine candidate sites found by Digenome-seq (Fig. 28)  
In this study, we developed Sniper screen in E. coli to create a SpCas9 
variant with increased specificity and full on-target activity. The specificities of other 
DNA endonucleases that induce DSBs, such as SaCas9 or Cpf1s, could also be 
improved by using Sniper-screen. It is expected to be available as a means to further 
improve the variants of the present. We also expect to find better variants by 
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인간과 여러 동식물들의 게놈 지도가 완성되면서 유전체 조절에 대한 
관심이 올라가게 되었다. 유전학에서는 세포 수준에서 발현되는 유전자의 조절
이 필수 불가결한 요소이다. 다양한 유전자의 기능이 밝혀지고, 질병과 관련된 
유전자의 조절을 하는 데 많은 연구가 진행됨에 따라 유전자를 표적으로 할 수 
있는 Zinc finger nuclease, TALE nuclease, CRISPR-Cas9과 같은 유전자 결합 단
백질에 대한 연구도 활발히 진행되고 있다. 
CRISPR-Cas9은 다루기 쉽고, 효율도 좋은 강력한 단백질 시스템으로 
자리잡고 있으나, 목표한 유전자가 아닌 비특이적인 결합으로 다른 유전자와 결
합을 할 수 있다는 단점이 있다. 이를 해결하기 위해서 특이성이 올라간 Cas9
을 개발하는 연구들이 진행되고 있다. 주된 연구 방식으로는 구조적 정보를 기
반으로 RNA와 보다 정확하게 결합할 수 있도록 단백질의 정보를 바꿔주는 합
리적인 디자인 방법과 임의의 돌연변이를 정보를 넣어주고 이를 대장균과 같은 
생물체를 이용하여 유도진화를 통해서 목표로 하는 단백질을 얻어내는 방식이 
있다. 
이번 연구에서는, 대장균을 숙주로 유도 진화 방법을 이용하여 정확성
이 향상된 Cas9 단백질을 만드는 일을 진행하였다. 한 번에 양성선택과 음성선
택을 동시에 진행할 수 있는 Sniper 스크리닝을 고안하고 이를 이용해서 목표
로 하는 단백질인 Sniper-Cas9을 선별해 낼 수 있었다. 선별한 후 기존에 개발
된 여러가지 Cas9 단백질들과 비교를 통해서 찾아낸 Sniper-Cas9이 정확성이 
향상되었고 다른 단백질들은 사용할 수 없는 여러가지 sgRNA와도 문제 없이 
결합을 할 수 있다는 것을 확인하였다. 
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